Abstract
Abstract Antibodies can be used to deliver bioactive molecules (drugs, cytokines, photosensitizers, radionuclides, etc.) to the tumor environment, thus sparing normal tissues. The targeting of modified sub-endothelial extracellular matrix components using armed antibodies is particularly attractive, because of: (i) the abundance and stability of some of these antigens (e.g., splice isoforms of fibronectin and tenascin-C); (ii) the dependence of cancer on new blood vessels (iii) accessibility of these structures from the blood-stream (iv) the fact that some of these antigens are very aboundant in many different cancer types, while being virtually undetectable in most normal adult tissues. Advanced preclinical and clinical data on armed antibodies will be presented in this lecture.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
